Hints and tips:
Related Special Reports
...The lesson for other chairs and managers could be that Blanc, as it sounds she is accustomed to doing, pragmatically took these comments on the chin while the individuals weren’t stopped, asked to apologise...
...SmithKline Beecham (now part of GSK) pulled its successful Lyme disease vaccine in the early 2000s amid rising anti-vaccine sentiment....
...Shareholder discontent hit a high note at the conglomerate earlier this year following news of Unilever’s three failed approaches to buy UK drugmaker GlaxoSmithKline’s consumer health business, landing its...
...Also announcing a new chair this morning is GlaxoSmithKline’s consumer health business, due to be demerged from the pharmaceutical group next year....
...He made an opening offer for GlaxoSmithKline and Pfizer’s consumer health division in early November, hoping to snap up the business before it was spun off on to the public market....
...Russia may yet emerge as a battleground for activists in UK plc....
...Narasimhan is doing “all the right things . . . this is a much better invested business than it was, the market share performance looks much better, it’s a business communicating better with stakeholders...
...One plus point of next year’s demerger for GSK (as well as separating two businesses that appeal to very different types of investor) is to send debt with the consumer business’s cash flows....
...She didn’t overpay for the Pfizer consumer assets — and ended up doing the joint venture which was good for both parties,” he said....
...However, business and freelance groups remain worried....
...We’ve said that as long as the pandemic is raging, we’ll continue doing it at no profit.” AstraZeneca does not own the ChAdOx1 platform behind the vaccine, which belongs to Oxford spinout Vaccitech....
...Ms Walmsley is doing the right things....
...He is paying just over six times ebitda for Interserve’s main business....
...More than half of that provision related to business lending, which accounted for 11 per cent of the overall loan book....
...It picked the Cambridge-based drugs group despite its limited presence in the vaccine market compared with UK peer GlaxoSmithKline — which, as the world’s biggest vaccine manufacturer by sales, would have...
...Is there another big UK company that has been half as disappointing as GlaxoSmithKline?...
...And the regulator is now doing something about it....
...But doing so is premature. GSK chief executive Emma Walmsley will probably be irritated by the timing. Shares are up nearly 18 per cent this year....
...Mr Polman’s last significant act is likely to be a medium-sized acquisition to build out Unilever’s presence in India; it is the finalist in talks to buy GlaxoSmithKline’s consumer nutrition business, which...
...Income-hungry investors will have paid close attention to recent results from Royal Dutch Shell and pharmaceutical companies GlaxoSmithKline and AstraZeneca, as well as updates from Diageo, British American...
...Also difficult were my four years as a consultant to GSK [following the sale of the business]. Very few people there had a true understanding of the sector as I did....
...The experiment reflects a shift in the pattern and economics of illness, which has forced big pharma to reconsider business models that have served it well for decades....
...Other big pharma companies doing well according to the report include Pfizer, Novartis and Sanofi....
...And the business is growing fast organically and by acquisition, with clearance for a £240m takeover of Hungry House. It is doing it profitably, too....
...The economic calendar for Wednesday is just doing its own thing (all times London): 07.45: France consumer confidence08.00: Spain retail sales09.00: Italy business confidence09.30: UK Q2 GDP, mortgage approvals...
International Edition